CD138, syndecan-1, is a transmembrane proteoglycan with a main cellular expression in stratified and simple epithelia. Within the hemopoietic system, CD138 is mainly confined to late stages of B-cell differentiation. CD138 expression is reduced during malignant transformation of various epithelia, and CD138 is rapidly shed by myeloma cells entering into apoptosis. This antibody is a useful aid for classification of multiple myeloma. Anti-CD138 may also be useful for the subclassification of diffuse large B-cell lymphomas.
This product is not available for purchase by the general public.
High lot to lot consistency
Optimized for immunohistochemistry (IHC) with validated protocols
Certified manufacturing facilities guarantee full quality control
More than 50 years experience ensuring quality and innovation in antibodies and reagents
A mixture of U266 and XG-1 human myeloma cell lines (2, 8). See package insert for reference(s).
Monoclonal mouse antibody provided in liquid form as cell culture supernatant dialysed against 0.05 mol/L Tris-HCl, pH 7.2, and containing 15 mmol/L NaN3.
Anti-CD138, MI15, was included in the Sixth International Workshop and Conference on Human Leucocyte Differentiation Antigens (Kobe 1996), and studies by a number of different laboratories confirmed its reactivity with CD138 (1).
The epitope recognized by anti-CD138, MI15, is found within the ectodomain (extracellular part) of the CD138 core protein. Blocking experiments have revealed that the epitope recognized by MI15 seems to be partly overlapping the epitope recognized by another antibody to CD138, clone B-B4 (1, 5). Anti-CD138, MI15, reacts strongly with CD138 expressed by multiple myeloma-derived cell lines, such as U266 and XG-1 (8).
The focus of the sixth edition of the IHC Guidebook is to provide a comprehensive immunohistochemistry (IHC) resource for lab managers, lab technicians, learning pathologists, and students from around the world.